Asset
OLINCIGUAT
Cyclerion Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03285178 | phase2 | completed | 2017-12-22 | 2020-07-22 | Cyclerion Therapeutics | A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) |
| NCT02792998 | phase1 | completed | 2016-05-01 | 2016-11-01 | Cyclerion Therapeutics | A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects |
| NCT02572349 | phase1 | completed | 2015-10-01 | 2015-12-01 | Cyclerion Therapeutics | Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.